Efficacy of urapidil combined with oxiracetam in the treatment of patients with acute cerebral hemorrhage

Li Junqing; Hong Li; Niu Yanguo

doi:10.3969/j.issn.1672-8157.2025.05.005

Abstract：Objective To investigate the clinical efficacy of urapidil injection combined with oxiracetam in the treatment of patients with acute cerebral hemorrhage.Methods A retrospective study method was employed.A total of 116 patients with acute cerebral hemorrhage admitted to Anyang District Hospital in Puyang city from August 2021 to August 2024 were divided into the control group(treated with oxiracetam alone)and the observation group(treated with oxiracetam combined with urapidil injection)according to the treatment methods,with 58 cases in each group.Both groups underwent continuous treatment for 2 weeks.The neurological functions,the volumes of cerebral hematoma and cerebral edema,oxidative stress indicators,inflammatory factors and adverse reactions were compared between the two groups.Results After treatment,the National Institutes of Health Stroke Scale(NIHSS)scores decreased and the Glasgow Coma Scale(GCS)scores increased in both groups compared with those before treat-ment,and the NIHSS score and GCS score in the observation group((9.56±1.92)points,(13.02±1.84)points,respectively)were both better than those in the control group((12.94±2.87)points,(10.23±1.56)points,respectively)(t=7.455,8.808,both P<0.05).After treatment,the volumes of cerebral hematoma and cerebral edema in both groups decreased compared with those before treat-ment,and the observation group showed lower volumes of cerebral hematoma and cerebral edema((9.32±2.85)mL,(8.89±1.95)mL,respectively)compared with those of the control group((12.45±2.67)mL,(13.06±3.12)mL,respectively)(t=6.104,8.632,both P<0.05).After treatment,malondialdehyde(MDA)levels decreased and superoxide dismutase(SOD)levels increased in both groups compared with pre-treatment levels,and the observation group exhibited lower MDA levels((3.56±0.95)μmol·L-1)and higher SOD levels((107.56±7.45)U·mL-1)compared with those of the control group((4.12±0.98)μmol·L-1 and(91.24±8.12)U·mL-1,respective-ly)(t=3.125,11.279,both P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α)and high-sensitivity C-reactive pro-tein(hs-CRP)decreased in both groups compared with pre-treatment levels,and the observation group had lower levels of TNF-α and hs-CRP((34.72±6.13)pg·mL-1,(3.64±0.65)mg·L-1,respectively)compared with those of the control group((42.36±5.86)pg·mL-1,(4.52±0.69)mg·L-1,respectively)(t=6.861,7.070,both P<0.05).The incidence of adverse reactions in the observation group and the control group was 6.90%and 12.07%respectively,with no statistically significant difference(χ2=0.940,P>0.05).Conclusion The combination of urapidil injection and oxiracetam in the treatment of patients with acute cerebral hemorrhage demonstrates good ef-ficacy,improving neurological function,accelerating hematoma absorption,alleviating oxidative stress and inflammatory responses,with favorable safety.